As part of one of the best developmental therapeutics programs in the country, our clinical pharmacologists conduct more clinical trials than any pediatric cancer center in the nation and are leaders in the development of new chemotherapy treatments for pediatric cancer.
Texas Children’s clinical pharmacologists have developed a number of new anti-cancer agents currently undergoing clinical trials within the Cancer Center. Many of the clinical trials performed at Texas Children’s Cancer Center are supported in part by the hospital’s National Institutes of Health-supported General Clinical Research Center (GCRC).
Texas Children’s Cancer Center pharmacologists received a grant of nearly $1.5 million from the National Institute of Child Health and Human Development to fund the Texas Children’s Pediatric Pharmacology Research Unit (PPRU). This unit conducts studies to assure the safety of drug treatments in children.
More than 260 treatment studies
Texas Children’s Cancer and Hematology Centers have more than 260 clinical trials underway to determine the safety and effectiveness of drug treatments in children. Approximately, 80% of our patients are involved in clinical trials. Our Developmental Therapeutics Program has developed a number of new anti-cancer agents currently undergoing clinical trials within Texas Children’s Cancer and Hematology Centers, which means our patients have access to the newest and most advanced therapies.
Every patient is considered for leading-edge therapies
Recognizing that clinical trials are the standard of care for all children with cancer, every eligible patient is considered for entry in National Cancer Institute-approved trials, and the vast majority are registered in these studies. These treatment protocols represent leading-edge therapies in the field, to provide the best treatments for children with cancer.
Featured Clinical Trials
ADVL1114: A Phase 1 Study of Temsirolimus in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
Patients must have 2nd or greater relapse of pre-B ALL, T-cell ALL, lymphoblastic lymphoma, or peripheral T-cell lymphoma.
PBTC-033: A Phase I/II Study of ABT-888, an Oral Poly (ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas
Stay Up-to-Date: Subscribe to our e-Newsletter
Our Clinical Trials e-Newsletter is designed to provide you with information regarding the latest clinical trials available at Texas Children’s Cancer and Hematology Centers.